0 citations
Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial
SSRN Electronic Journal2020
Citations Over Time
J. Guigay, Anne Aupérin, Jérôme Fayette, Esma Saâda-Bouzid, Cédrik Lafond, Miren Taberna, Lionnel Geoffrois, Laurent Martin, Olivier Capitain, Didier Cupissol, H. Castanie, Damien Vansteene, Philippe Schafhausen, Alison Johnson, Caroline Even, Christian Sire, Sophie Duplomb, Camille Evrard, Jean‐Pierre Delord, Brigitte Laguerre, Sylvie Zanetta, Cécile Chevassus, Aldéric Fraslin, Fanny Louat, Laura Sinigaglia, Ulrich Keilholz, Jean Bourhis, Ricard Mesı́a, AIO GORTEC
Related Papers
- → SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells(2017)75 cited
- → Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma(2014)60 cited
- → The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy(2021)18 cited
- → Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment‐induced reduction in EGFR, pEGFR, and pSrc(2016)8 cited
- → Data from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma(2023)